Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab biosimilar + pertuzumab biosimilar with XELOX for HER2-positive locally advanced rectal cancer
ChiCTR2500099967Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pertuzumab, oxaliplatin and capecitabine in rectal adenocarcinoma, sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500099967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099967.